news

CHADDS FORD, Pa. and CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ — Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) and DURECT Corporation (Nasdaq: DRRX), announced today that they have signed an agreement to collaborate on the development and commercialization of DURECT’s CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the U.S. and Canada. The companies believe CHRONOGESIC has significant potential […]

CUPERTINO, Calif., Oct 30, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets 13th Annual Health Care Conference. The conference is being held at The Plaza Hotel in New York City. Dr. James E. Brown, Chief Executive Officer, will be presenting at the conference

CUPERTINO, Calif., Oct 16, 2002 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 11th, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., Oct 4, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Life Sciences Conference. The conference is being held at The Plaza Hotel in New York City. Thomas A. Schreck, Chief Financial Officer, will be presenting at the conference on Monday, October

CUPERTINO, Calif., Aug 26, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that, following discussions between DURECT and the FDA on DURECT’s on-going Phase III clinical trial for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, the FDA has requested that the clinical trial protocol be amended to provide for additional patient monitoring before

CUPERTINO, Calif., Aug 5, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill – 22nd Annual Summer Seminar. The conference is being held at The Boston Marriott Long Wharf Hotel. Dr. James E. Brown, President and Chief Executive Officer will be presenting at

CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended June 30, 2002 was $9.9 million or 21 cents per share, compared to $21.0 million or 45 cents per

CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) and Voyager Pharmaceutical Corporation announced today that the two companies have signed a development and commercialization agreement to develop Voyager’s patented product, using leuprolide acetate for the treatment of Alzheimer’s disease. Voyager owns the patent rights to the use of a broad

CUPERTINO, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing of patients in the first clinical trial of its pivotal Phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System. The CHRONOGESIC product is a pain relief system that continuously delivers sufentanil systemically for three

CUPERTINO, Calif., Jul 8, 2002 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 29, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive